Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04861506
Other study ID # The Resolve Study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2025

Study information

Verified date April 2021
Source First People's Hospital of Hangzhou
Contact xin Fang
Phone +08613867478324
Email hzfhfx@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.


Description:

According to the Trans-Atlantic Inter-Society Consensus (TASC) II guidelines, acute arterial occlusion which in stage IIb was recommended for thrombectomy. However, with the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, stage IIb patients and some subacute thromboembolic lesions were also effective in some retrospective studies. Despite The shift of Endovascular-first strategy has been documented in recent literature. There still lack evidence to support either approach have a significant advantage over the thrombectomy. And stage IIb lesions and subacute lesions are often excluded in prospective clinical trials. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date December 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients over 18 years old. 2. acute or subacute limb ischemia patients with Rutherford classification stage range from I to IIb. 3. Patients with Rutherford classification range from 3 to 5. 4. The guide wire should pass through the lesion of femoropopliteal artery, and further endovascular treatment is performed. In this study, we did not limit the methods of the guide wire passing through the target lesion. After the angiography and/or performed under digital subtraction angiography(DSA) which confirmed the existing of thrombus, and which is related to occlusions of lower extremity or in-stent restenosis. 5. Pharmacomechanical thrombectomy (PMT) and/or catheter-directed thrombolysis (CDT) was or were used for thrombus removal. 6. The lower extremity artery needs to have a healthy runoff of no less than 10 cm above the ankle, and at least one healthy dorsalis pedis artery, medial or lateral plantar artery connected with the digital artery below the ankle. 7. Informed consent signed by patients. Exclusion Criteria: 1. acute or subacute limb ischemia patients with Rutherford classification stage III. 2. Patients with thromboangiitis obliterans. 3. Patients with failure of endovascular treatment, and transfer to open surgery or hybrid operation. 4. People with stroke, cerebral hemorrhage, gastrointestinal bleeding or myocardial infarction and so on in the past 3 months. 5. Patients with known allergy to heparin, low molecular weight heparin and contrast agents. 6. Patients with high bleeding risk. 7. Women during pregnancy and lactation. 8. Patients with other diseases that may lead to difficulties in the trial or significantly shorten the life expectancy (< 2 years), such as tumors, severe liver disease, cardiac insufficiency. 9. Patients who have been enrolled in other clinical trials in the past 3 months. 10. Patients who are unwilling or refuse to sign the informed consent form. -

Study Design


Intervention

Procedure:
endovascular treatment
All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods such as pharmacomechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) for thrombus removal according to the characteristics of the lesions and hospital conditions.

Locations

Country Name City State
China Fan xin Hangzhou Zhejiang

Sponsors (9)

Lead Sponsor Collaborator
First People's Hospital of Hangzhou Chengdu University of Traditional Chinese Medicine, First Affiliated Hospital of Zhejiang University, Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology, Qingdao haici hospital, RenJi Hospital, Second Affiliated Hospital of Suzhou University, Shanghai Zhongshan Hospital, Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Amputation-free survival The amputation-free survival after endovascular surgery post-interventional 12months
Primary Adverse events at post-interventional 1months the incidence of amputation, operation-related distal embolism, rethrombosis, acute renal failure and/or death. post-interventional 1 months
Secondary Technical success rate Technical success rate Post operation up to 1 day
Secondary Clinical-driven Target lesion reintervention(CD-TLR) rate Clinical-driven Target lesion reintervention rate post-interventional 1,3,6,12 months
Secondary Clinical-driven Target vascular reintervention(CD-TVR) rate Clinical-driven Target vascular reintervention rate post-interventional 1,3,6,12 months
Secondary The total time used in the operation The total time used in the operation Intraoperative
Secondary Primary patency(PP)of the lesions Primary patency(PP)of the lesions post-interventional 1,3,6,12 months
Secondary Changes of quality of life assessed by VascuQol scale Changes of quality of life post-interventional 1,3,6,12 months
Secondary Direct medical expenses (2-year cumulative hospitalization expenses and endovascular expenses related to target lesions) Direct medical expenses 2 years
See also
  Status Clinical Trial Phase
Completed NCT04485481 - Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers Phase 1
Completed NCT03473236 - Phase 1A Safety Trial of Inhaled PK10571 (GB002) Phase 1
Not yet recruiting NCT03683953 - The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells Phase 1
Recruiting NCT05546567 - NOPARK Open Label Extension Study N/A
Recruiting NCT05413226 - Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility N/A
Recruiting NCT05112159 - Study of IPG1094 in Healthy Participants Phase 1
Completed NCT04689035 - A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 Phase 1
Completed NCT04335045 - Phase I Study of PH100 (Ecklonia Cava Phlorotannins) Phase 1
Completed NCT05037227 - Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
Recruiting NCT05517291 - DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease N/A
Enrolling by invitation NCT06446778 - Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Completed NCT05585463 - Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
Completed NCT04188821 - Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander N/A
Completed NCT03667430 - Safety Evaluation of Porous Silica in Men N/A
Completed NCT04499482 - Safety and Tolerability of Soy Fiber N/A
Completed NCT03141905 - Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease N/A
Completed NCT05244161 - A Quasi-experimental Evaluation of the Malezi Program in Tanzania N/A
Recruiting NCT03791372 - Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy Phase 1
Not yet recruiting NCT04774900 - Standardization of Ambulance Equipment